To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease
Clinical trial NCT04143958 · WITHDRAWN
Trial details
- NCT number
- NCT04143958
- Sponsor
- Sanofi
- Status
- WITHDRAWN
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2020-09-01
- Primary completion
- 2023-11-01
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.